WASHINGTON, Feb. 6, 2017 /PRNewswire/ -- Minneapolis-based StemoniX, Inc. will present research demonstrating superiority of their microHeart® microplates over industry-standard cultureware as a control. With microHeart, cardiomyocytes passively aligned into physiologically relevant structures that more closely represented human heart tissue, meeting a critical need for drug toxicity and efficacy screening.
Human induced pluripotent stem cells are increasingly used in drug discovery. Yet widespread adoption is limited by cost and scaling for high throughput. Challenges remain to identify a platform that closely predicts clinical efficacy and toxicity in humans. Organizations want to eliminate animal testing and more accurately identify clinical drug candidates, so a relevant model is critical.
StemoniX will present new data about microHeart February 7 in the scientific session "Automation and High-throughput Technologies" at the annual International Conference and Exhibition of the Society for Laboratory Automation and Screening. A key finding includes that cardiac cells plated in microHeart emulate correct cardiac muscle fiber organization leading to features of accelerated cell maturity.
Ping Yeh, StemoniX CEO, "We are excited to launch microHeart as a transformational advance in this field. It is critical that we offer a physiologically relevant model and that we provide it economically for scalable incorporation into drug screening workflow."
StemoniX will exhibit at SLAS2017 in Booth #1523 and as a selected company in Innovation AveNEW.
Our mission is to accelerate the discovery of new medicines with physiologically-relevant, structured human cells in high density plates. We develop and manufacture human induced pluripotent stem cell (iPSC) derived cardiac and neuronal platforms for high throughput drug toxicity and efficacy screening. Predictive, accurate, and consistent, our human models enable scientists to quickly and economically conduct research in a simplified workflow. Our new microHeart® products provide researchers with structurally aligned cardiac cells resembling native human heart tissue with accelerated features of cell maturity, essential in predicting drug toxicity and efficacy. We also collaborate with drug discovery organizations to operationalize their human cells for high throughput screening. With leading-edge iPSC technologies, we are helping global institutions bring the most promising medicines to patients. Visit StemoniX.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cardiac-drug-toxicity-and-discovery-screening-reaches-new-relevance-with-launch-of-microheart-at-slas2017-300402207.html